StockRing.com   Home    DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH   
  iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   
 9/18/2014, (NASDAQ:MRK), $60.31 +0.43, +0.72%, "BUY" Merck & Compan Stock
 




  
  

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

On   9/18/2014   StockRing.com recommends to   "BUY"   MRK   stock at current price of   $60.31.
Today MRK stock opened at $60.11 and was trading in the daily range of $ 15808 per share.
Merck & Compan (NASDAQ:MRK) Market capitalization is $174.0B. MRK average daily volume is N/A.
On last trading session MRK stock traded 8,004,138 shares. Also the Short Ratio for (NASDAQ:MRK) stock is 43.550B.
Last year Merck & Compan(NASDAQ:MRK) before taxes (EBITDA) (ttm) earned $60.80 on revenue of $3.59.
MRK 50-Day Moving Average is $15.950B vs. $60.31 now and 200-Day Moving Average is $58.82 vs. $60.31.
--------------------------------------------------------------------------------------------------------------------
VIX is "HOLD".  Nasdaq is "HOLD".  S&P 500 is "HOLD" on  5/16/2014
--------------------------------------------------------------------------------------------------------------------
MRK Earnings Per Share - EPS (ttm) is 1.9. MRK Stock Price Per Earnings ratio - P/E is 31.55.
Merck & Compan(NASDAQ:MRK) stock pays a dividend of $ " per share which is a yield of "NYSE"%.
On average analysts predict that One Year Target Estimated price for MRK stock is $57.6.
In the last 52 weeks MRK stock was trading in the range of $44.62 - 61.33.
 
 
  Our FREE iPhone App Buy-Sell-Hold ratings for 4568 stocks & ETFs:
 
1. DOW30+    Part 1    199 Stocks    Updated: 5/16/2014 6:13:26 PM
2. DOW30+    Part 2    192 Stocks    Updated: 5/16/2014 6:18:11 PM
3. DOW30+    Part 3    193 Stocks    Updated: 5/16/2014 6:23:19 PM
4. DOW30+    Part 4    195 Stocks    Updated: 5/16/2014 6:27:30 PM
 
5. ENERGY    Part 1    188 Stocks    Updated: 5/30/2014 10:49:50 AM
6. ENERGY    Part 2    186 Stocks    Updated: 5/30/2014 10:45:38 AM
7. ENERGY    Part 3    196 Stocks    Updated: 5/30/2014 10:40:22 AM
 
8. HEALTH    Part 1    184 Stocks    Updated: 5/19/2014 11:03:20 PM
9. HEALTH    Part 2    138 Stocks    Updated: 5/19/2014 11:06:54 PM
 
10. FINANCE    Part 1    191 Stocks    Updated: 5/29/2014 9:02:46 AM
11. FINANCE    Part 2    190 Stocks    Updated: 5/29/2014 9:08:02 AM
12. FINANCE    Part 3    188 Stocks    Updated: 5/29/2014 9:13:08 AM
13. FINANCE    Part 4    188 Stocks    Updated: 5/29/2014 9:17:57 AM
14. FINANCE    Part 5    190 Stocks    Updated: 5/29/2014 9:22:59 AM
 
15. SERVICE    Part 1    181 Stocks    Updated: 5/22/2014 12:09:15 AM
16. SERVICE    Part 2    185 Stocks    Updated: 5/22/2014 12:10:17 AM
17. SERVICE    Part 3    183 Stocks    Updated: 5/22/2014 12:02:57 AM
18. SERVICE    Part 4    193 Stocks    Updated: 5/22/2014 12:07:53 AM
 
19. TECH    Part 1    187 Stocks    Updated: 5/20/2014 10:04:33 AM
20. TECH    Part 2    183 Stocks    Updated: 5/20/2014 10:10:24 AM
21. TECH    Part 3    184 Stocks    Updated: 5/20/2014 10:15:47 AM
22. TECH    Part 4    102 Stocks    Updated: 5/20/2014 10:27:15 AM
 
23. IPOs    200 Stocks    Updated:  TODAY , 6/10/2014 3:37:13 AM
 
24. ETFs    Part 1    193 Stocks    Updated: 5/16/2014 6:48:58 PM
25. ETFs    Part 2    191 Stocks    Updated: 5/16/2014 6:52:54 PM
26. ETFs    Part 3    157 Stocks    Updated: 5/16/2014 6:56:31 PM

BUY  DOW 30+:    ENERGY: ADMA  RNG  CDW  CBA  BLUE     HEALTH: ACWX  EPHE  FM  DVYA  AOM 
      FINANCE: XLK  DWX  BWZ  GII  SCPB     SERVICES: UST  MLPX  BRAQ  YCL  EMFM     TECH: CSGP  WDC  ONNN  RENN  JNPR 
SELL  DOW 30+: GGB     ENERGY: RMAX  SEAS  NBCB  PETX  VOYA     HEALTH: ITA  ICLN  EIRL  SCZ  PICK 
      FINANCE: XME  XSW  KBE  EWO  BAL     SERVICES: VIXM  EEV  UVXY  QID  AGQ     TECH: BRKR  CPHD  IPGP  LLTC  MDRX 


Samples of StockRing Real Time "Buy-Sell-Hold" stock Ratings:



  Enter Stock:  
  
    
    
 
 



Download StockRing Free  Buy-Sell-Hold iPhone
App for 1,200 stocks in Energy Healthcare Finance Services & Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH

  Our FREE iPhone App Buy-Sell-Hold ratings for 4568 stocks & ETFs:
 
1. DOW30+    Part 1    199 Stocks    Updated: 5/16/2014 6:13:26 PM
2. DOW30+    Part 2    192 Stocks    Updated: 5/16/2014 6:18:11 PM
3. DOW30+    Part 3    193 Stocks    Updated: 5/16/2014 6:23:19 PM
4. DOW30+    Part 4    195 Stocks    Updated: 5/16/2014 6:27:30 PM
 
5. ENERGY    Part 1    188 Stocks    Updated: 5/30/2014 10:49:50 AM
6. ENERGY    Part 2    186 Stocks    Updated: 5/30/2014 10:45:38 AM
7. ENERGY    Part 3    196 Stocks    Updated: 5/30/2014 10:40:22 AM
 
8. HEALTH    Part 1    184 Stocks    Updated: 5/19/2014 11:03:20 PM
9. HEALTH    Part 2    138 Stocks    Updated: 5/19/2014 11:06:54 PM
 
10. FINANCE    Part 1    191 Stocks    Updated: 5/29/2014 9:02:46 AM
11. FINANCE    Part 2    190 Stocks    Updated: 5/29/2014 9:08:02 AM
12. FINANCE    Part 3    188 Stocks    Updated: 5/29/2014 9:13:08 AM
13. FINANCE    Part 4    188 Stocks    Updated: 5/29/2014 9:17:57 AM
14. FINANCE    Part 5    190 Stocks    Updated: 5/29/2014 9:22:59 AM
 
15. SERVICE    Part 1    181 Stocks    Updated: 5/22/2014 12:09:15 AM
16. SERVICE    Part 2    185 Stocks    Updated: 5/22/2014 12:10:17 AM
17. SERVICE    Part 3    183 Stocks    Updated: 5/22/2014 12:02:57 AM
18. SERVICE    Part 4    193 Stocks    Updated: 5/22/2014 12:07:53 AM
 
19. TECH    Part 1    187 Stocks    Updated: 5/20/2014 10:04:33 AM
20. TECH    Part 2    183 Stocks    Updated: 5/20/2014 10:10:24 AM
21. TECH    Part 3    184 Stocks    Updated: 5/20/2014 10:15:47 AM
22. TECH    Part 4    102 Stocks    Updated: 5/20/2014 10:27:15 AM
 
23. IPOs    200 Stocks    Updated:  TODAY , 6/10/2014 3:37:13 AM
 
24. ETFs    Part 1    193 Stocks    Updated: 5/16/2014 6:48:58 PM
25. ETFs    Part 2    191 Stocks    Updated: 5/16/2014 6:52:54 PM
26. ETFs    Part 3    157 Stocks    Updated: 5/16/2014 6:56:31 PM

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

Our FREE iPhone App with Buy-Sell-Hold ratings for 4,030 stocks:

  iPhone App Buy-Sell-Hold Ratings for 5-5-2013
           
           
           
           
     
  

 
  Enter Stock:  
  
    
    
 



9/18/2014  Thursday, September 18, 2014 (Irvine, California) Today StockRing.com Recommendation is to "BUY"for Merck & Compan (NASDAQ:MRK) Stock. MRK stock opening price was $60.11 per share. Current price of NASDAQ:MRK Stock is $60.31 per share and it is $+0.43, (+0.72%) today and it was trading in the daily range of $15808 per share. Current Bid Price for (NASDAQ:MRK) stock is $2.94 and the Ask Price is $60.01. In the last 52 weeks MRK stock was trading in the range of $44.62 - 61.33. 50-Day Moving Average for (NASDAQ:MRK) stock is $15.950B and 200-Day Moving Average is $58.82. On average analysts predict that One Year Target Estimated price for (NASDAQ:MRK) stock is $57.6.

Merck & Compan (NASDAQ:MRK) is rated as a buy on 9/10/2014 1:20:56 AM.

Merck & Compan (NASDAQ:MRK) Market capitalization is $174.0B. (NASDAQ:MRK) stock average daily volume is N/A shares per day. However, on last trading session of Sep 18, 2012 MRK stock traded 8,004,138 shares. Also The Number of days it would take short sellers on average to repurchase all the borrowed shares or Short Ratio for (NASDAQ:MRK) stock is 43.550B. On previous trading session MRK Stock closed at $59.88 per share.

Last year Merck & Compan (NASDAQ:MRK) before taxes (EBITDA) (ttm) earned $60.80 on total revenue of $3.59. Earnings Per Share - EPS (ttm) for MRK stock is 1.9. Also, (NASDAQ:MRK) Stock Price Per Earnings ratio - P/E is 31.55. Thus, (NASDAQ:MRK) Stock Price/Sales (ttm) ratio is 62.61 and Price/Book (mrq) ratio is 3.97.

(NASDAQ:MRK) Stock pays a dividend of $ " per share which is a yield of "NYSE"%. So at this time (NASDAQ:MRK) Stock maintains Trailing Annual Dividend Rate at 3.00.


StockRing Recommendations for Merck & Compan (NASDAQ:MRK) Stock are updated daily here

http://StockRing.com/sr/Buy-Sell-Hold-Stock-Analysis-Ratings.asp?StockName=MRK

At this time StockRing recommends to buy LONG positions on many stocks from Dow 30+ stocks that currently have a BUY or SUPER BUY rating. If you decide to take a SHORT position and actually sell some stocks sjort right now - please check the section of Dow 30+ stocks that have a SELL or SUPER SELL rating.

If you would like to receive Buy-Sell-Hold ratings for stocks from Energy, Healthcare, Finance, Services & Hi-Tech sectors on your iPhone, then please download Buy-Sell-Hold iPhone App here:


Free Limited or $10 Full Version  Buy-Sell-Hold iPhone App
for 1,200 stocks in Energy, Healthcare, Finance, Services and Tech


DOW 30+

ENERGY

HEALTH

FINANCE

SERVICES

TECH


 
  Enter Stock:  
  
    
    
 
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

NASDAQ:MRK Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

9/18/2014 1 Year Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Thursday, September 18, 2014
  
1 Year MRK 1 Year Dow Jones
1 Year Nasdaq 1 Year S&P 500
9/18/2014 5 days Stock market price chart for Merck & Compan (NASDAQ:MRK) Stock on Thursday, September 18, 2014
  
5 Days MRK 5 Days Dow Jones
5 Days Nasdaq 5 Days S&P 500
  

EUROs for $1 DOLLAR: 30 days
     

NASDAQ:MRK Stock Charts:   1d   5d   3m   6m   1y   2y   5y   Max    Options   More Info
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

9/18/2014 Stock market price quote data for Merck & Compan (NASDAQ:MRK) Stock on Thursday, September 18, 2014

Last Trade: 60.31
Trade Time: Sep 18
Change: +0.43, (+0.72%)
Prev Close: 59.88
Open: 60.11
Bid: 2.94
Ask: 1.76
1y Target Est: $57.6
50-Day Moving Average: 15.950B
200-Day Moving Average:
58.82
Short Ratio: 43.550B
Trailing Annual Dividend Rate: 3.00
Day's Range: 15808
52wk Range: 44.62 - 61.33
Volume: 8,004,138
Avg Vol: N/A
Market Cap: 174.0B
P/E (ttm): 31.55
EPS (ttm): 1.9
Div & Yield: " ("NYSE"%)
Revenue (ttm): 3.59
Earnings before Tax (EBITDA) (ttm): 60.80
Price/Sales (ttm): 62.61
Price/Book (mrq): 3.97
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

  
  
 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

MERCK CO INC(NYSE: MRK) Company Information

Merck & Co. Inc.
PO Box 100
One Merck Drive
Whitehouse Station, NJ 08889-0100
United States - Map
Phone: 908-423-1000
Fax: 908-735-1253
Web Site: http://www.merck.com

MERCK CO INC(NYSE: MRK) DETAILS

MERCK CO INC(NYSE: MRK) Index Membership: Dow Jones Composite Dow Industrials S&P 100 S&P 500 S&P 1500 Super Comp
MERCK CO INC(NYSE: MRK) Sector: Healthcare
MERCK CO INC(NYSE: MRK) Industry: Drug Manufacturers - Major
MERCK CO INC(NYSE: MRK) Full Time Employees: 52,700

MERCK CO INC(NYSE: MRK) BUSINESS SUMMARY

Merck & Co., Inc. provides products for human and animal health in the United States and internationally. The company?s Pharmaceutical segment offers human health pharmaceutical products, such as therapeutic and preventive agents. Its products comprise Singulair, a leukotriene receptor antagonist for the treatment of asthma and allergic rhinitis; Cozaar, Hyzaar, Vasotec, and Vaseretic, the hypertension and/or heart failure products; Fosamax and Fosamax Plus D for treating osteoporosis; Januvia and Janumet for type 2 diabetes; Cosopt and Trusopt, the ophthalmological products; Zocor, an atherosclerosis product; Maxalt for acute migraine; Propecia to treat male pattern hair loss; Arcoxia to treat arthritis and pain; Proscar to treat symptomatic benign prostate enlargement; and Emend for the prevention of chemotherapy-induced and post-operative nausea and vomiting. Merck & Co.?s Vaccines segment comprises human health vaccines, such as preventative pediatric, adolescent, and adult vaccines. Its products include Gardasil to prevent cervical cancer, pre-cancerous and low-grade lesions, vulvar and vaginal pre-cancers, and genital warts; Varivax to prevent chickenpox; ProQuad, a pediatric combination vaccine against measles, mumps, rubella, and varicella; M-M-R II, a vaccine against measles, mumps, and rubella; RotaTeq to protect against rotavirus gastroenteritis in children; Zostavax for preventing shingles; Primaxin and Cancidas, anti-bacterial/anti-fungal products; Isentress, Crixivan, and Stocrin, antiretroviral therapies for the treatment of HIV infection; and Invanz for the treatment of infection. Merck & Co. has research, collaboration, or licensing agreements with Neuromed Pharmaceuticals, Ltd.; ARIAD Pharmaceuticals, Inc.; GTX, Inc.; Idera Pharmaceuticals; Japan Tobacco Inc.; Galapagos NV; AstraZeneca plc; Metabasis Therapeutics Inc.; and Addex Pharmaceuticals Ltd. The company was founded in 1891 and is headquartered in Whitehouse Station, New Jersey.

MERCK CO INC(NYSE: MRK) KEY EXECUTIVES

Mr. Richard T. Clark , 63 Exec. Chairman, Chief Exec. Officer and Pres $ 4.03M $ 0

Mr. Peter N. Kellogg , 52 Chief Financial Officer and Exec. VP $ 1.60M $ 0

Mr. Kenneth C. Frazier , 54 Exec. VP and Pres of Global Human Health $ 2.00M $ 0

Dr. Peter Kim Ph.D., 50 Exec. VP and Pres of Merck Research Laboratories $ 1.91M $ 0

Mr. Bruce N. Kuhlik , 52 Exec. Vice president and Gen. Counsel $ 1.25M $ 0



9/18/2014 Latest stock market news data for Merck & Compan (NASDAQ:MRK) Stock on Thursday, September 18, 2014

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs

Sun Pharma, Merck & Co Inc enter into pact for Tildrakizumab
Economic Times - Sep 17, 2014
"Merck will continue all clinical development and regulatory activities, which will be funded by Sun Pharma. Upon product approval, Sun Pharma will be responsible for regulatory activities, including subsequent submissions, pharmacovigilance, post ...
Sun Pharma and Merck & Co. Inc. Enter into Licensing Agreement for ... - MarketWatch
Sun Pharma, Merck & Co Inc ink pact for Tildrakizumab - Moneycontrol.com
Merck Reports Progress In Type-2 Diabetes Drug Trials
Bidness ETC - 12 hours ago
Merck & Co., Inc. (MRK) announced yesterday, early results from its Phase III developmental program, which evaluated the efficacy and safety of omarigliptin for the treatment of type-2 diabetes.
First data from phase 3 study of investigational once-weekly DPP-4 inhibitor ... - News-Medical.net
MSD Presents First Phase 3 Data in Japanese Patients for Omarigliptin, an ... - Business Wire India (press release)
Sun Pharma, Merck & Co Inc enter into $80 mn drug licensing pact
Firstpost - Sep 17, 2014
New Delhi: Pharma major Sun Pharmaceutical Industries today entered into a licensing agreement with Merck & Co Inc for investigational therapeutic antibody candidate, tildrakizumab to be used for treatment of plaque psoriasis.
Sun Pharmaceutica shares end nearly 2 per cent up on Merck & Co Inc licensing ...
Economic Times - 11 hours ago
MUMBAI: Shares of Sun Pharmaceutical Industries today ended nearly 2 per cent higher after the company entered into a licensing agreement with Merck & Co Inc for using investigational therapeutic antibody candidate, tildrakizumab for treatment of ...
3 Reasons Merck & Co., Inc.'s Stock Could Fall
Motley Fool - Aug 28, 2014
If you were lucky enough to time your purchase of Merck (NYSE: MRK ) during the heights of the Great Recession, your investment has probably seen a return of 100% or greater.
Is it Time to Buy Merck & Co., Inc.'s Stock?
Motley Fool - Sep 4, 2014
Investors in pharmaceutical giant Merck (NYSE: MRK ) have to be liking what they've witnessed in recent years as Merck's stock has vaulted to its highest levels since prior to the Great Recession. However, back Merck's chart out to a 15-year view and ...
Merck Announces Positive Phase III Results For Odanacatib; Drug's Safety ...
Bidness ETC - Sep 16, 2014
Merck & Co., Inc. (MRK) announced yesterday, positive results from Phase III trials of its drug odanacatib, used to treat osteoporosis in postmenopausal women.
Merck & Co., Inc. Wins First Stage of the PD-1 Race
Motley Fool - Sep 5, 2014
Merck (NYSE: MRK ) has won the race to get the first immunotherapy drug that blocks the PD-1 pathway on the U.S. market. Today, the FDA approved pembrolizumab, which will go by the brand name Keytruda, for patients with advanced or unresectable ...
Merck Beats Bristol-Myers In Breakthrough Cancer Drug Race - Bidness ETC
FDA OKs Merck melanoma drug, 1st in its class - CNBC
Sun Pharma, Merck & Co enter agreement for Tildrakizumab
Business Standard - Sep 17, 2014
The US-based Merck & Co., Inc. and Sun Pharmaceuticals have entered into an exclusive worldwide licensing agreement for Merck's dermatology molecule - tildrakizumab (MK-3222), which is currently under phase 3 registration trials.
Bristol-Myers Squibb Co (BMY) Sues Merck & Co., Inc. (MRK) Over Cancer Drug ...
Insider Monkey (blog) - Sep 9, 2014
Bristol-Myers Squibb Co (NYSE:BMY) along with Ono Pharmaceutical launched a lawsuit against Merck & Co., Inc. (NYSE:MRK) last Thursday, claiming that the company's new cancer drug Keytruba (which was approved by the FDA the same day) violates ...
Bristol-Myers Sues Merck of Patent Infringement on Keytruda - Analyst Blog - NASDAQ

 
DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

 DOW 30+    ENERGY    HEALTH    FINANCE    SERVICES    TECH
  Up   iPhone   Ratings   Profile   Charts   Quotes   News   Blogs   VIX   

MRK rating is generated by our FREE iPhone App Buy-Sell-Hold+ that covers 4,030 stocks & ETFs


9/18/2014 News from StockRing Blog about Merck & Compan (NASDAQ:MRK) Stock on Thursday, September 18, 2014



Copyright © 2014 StockRing.com. All rights reserved.
Subscriber Agreement   Privacy Agreement   Stocks   MutualFunds   Form

Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither StockRing.com nor its partners shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the StockRing site, a user agrees not to redistribute the information found therein.